Renaissance Technologies LLC Has $363,000 Stock Holdings in Quince Therapeutics, Inc. (NASDAQ:QNCX)

Renaissance Technologies LLC cut its position in Quince Therapeutics, Inc. (NASDAQ:QNCX) by 7.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 483,902 shares of the company’s stock after selling 36,198 shares during the period. Renaissance Technologies LLC’s holdings in Quince Therapeutics were worth $363,000 at the end of the most recent reporting period.

Quince Therapeutics Price Performance

Shares of NASDAQ QNCX opened at $0.69 on Friday. Quince Therapeutics, Inc. has a fifty-two week low of $0.51 and a fifty-two week high of $1.43. The stock has a market cap of $29.99 million, a price-to-earnings ratio of -0.91 and a beta of 0.86. The company has a debt-to-equity ratio of 0.29, a quick ratio of 6.15 and a current ratio of 6.15. The firm’s 50-day simple moving average is $0.70 and its 200 day simple moving average is $0.81.

Quince Therapeutics (NASDAQ:QNCX) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.18) earnings per share for the quarter.

Insiders Place Their Bets

In other news, CEO Dirk Thye bought 77,500 shares of the company’s stock in a transaction on Thursday, August 29th. The shares were purchased at an average price of $0.69 per share, with a total value of $53,475.00. Following the transaction, the chief executive officer now directly owns 766,941 shares in the company, valued at $529,189.29. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, President Charles S. Ryan purchased 48,387 shares of the stock in a transaction that occurred on Tuesday, August 20th. The shares were bought at an average price of $0.65 per share, with a total value of $31,451.55. Following the acquisition, the president now owns 122,461 shares of the company’s stock, valued at $79,599.65. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Dirk Thye purchased 77,500 shares of the stock in a transaction that occurred on Thursday, August 29th. The stock was bought at an average cost of $0.69 per share, for a total transaction of $53,475.00. Following the acquisition, the chief executive officer now directly owns 766,941 shares in the company, valued at $529,189.29. This trade represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 158,887 shares of company stock valued at $105,609 in the last 90 days. 16.80% of the stock is currently owned by corporate insiders.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.